Galidesivir is under clinical development by BioCryst Pharmaceuticals and currently in Phase I for Ebolavirus Infections (Ebola Hemorrhagic Fever). According to GlobalData, Phase I drugs for Ebolavirus Infections (Ebola Hemorrhagic Fever) have a 62% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Galidesivir’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Galidesivir overview

Galidesivir (formerly BCX-4430) is under development for the treatment of broad-spectrum antiviral such as yellow fever virus, Ebola and Marburg virus and Zika virus. The drug candidate is administered through the intramuscular and intravenous route of administration. It is an adenosine analogue and RNA dependent-RNA polymerase inhibitor that has broad-spectrum antiviral activity and is developed by using structure-guided drug design method.

It was under development for the treatment of Coronavirus Disease 2019 (COVID-19).

BioCryst Pharmaceuticals overview

BioCryst Pharmaceuticals (BioCryst) is a biotechnology company that designs, optimizes and develops small molecule drugs that block critical enzymes in the pathogenesis of diseases. The company focuses on the treatment of rare diseases and develops drugs for infectious diseases and hereditary angioedema. The company’s other pipeline products include, BCX9930, BCX9250 and galidesivir (BCX4430). It integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through a process known as structure-guided drug design. BioCryst’s products include peramivir injections, which consist of Rapivab, Alpivab, Rapiacta, Orladeyo and Peramiflu for the treatment of Influenza. BioCryst is headquartered in Durham, North Carolina, the US.

For a complete picture of Galidesivir’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.